Arcinova, a Quotient Sciences company and UK-based contract research development and manufacturing organisation (CRDMO), has ...

SOM Biotech has received a positive opinion from the European Medicines Agency’s Committee for Orphan Medical Products for SOM3355, a candidate therapy for Huntington’s disease (HD). The molecule ...

Merck has announced positive phase 3 results for Capvaxive, its 21-valent pneumococcal conjugate vaccine, in children and ...

Lundbeck has presented new clinical data on eptinezumab at the 2025 International Headache Congress in São Paulo, ...

Dr Deepika Jalota, Chief Development Officer, said: “These phase 2 PYNNACLE interim trial data illustrate that rezatapopt, a ...

Abcuro Inc, a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer ...

Thierry Van Nieuwenhove, CEO at Quotient Sciences, said: “This is a pivotal moment for RNA drug development. The combined ...

Bluejay Therapeutics has enrolled the first patient in AZURE-2, a global phase 3 clinical trial evaluating brelovitug ...